Cannabis (marijuana) has been proposed as treatment for a widening spectrum of medical conditions and has many properties that may be applicable to the management of amyotrophic lateral sclerosis (ALS). This study is the first, anonymous survey of persons with ALS regarding the use of cannabis. There were 131 respondents, 13 of whom reported using cannabis in the last 12 months. Although the small number of people with ALS that reported using cannabis limits the interpretation of the survey findings, the results indicate that cannabis may be moderately effective at reducing symptoms of appetite loss, depression, pain, spasticity, and drooling. Cannabis was reported ineffective in reducing difficulties with speech and swallowing, and sexual dysfunction. The longest relief was reported for depression (approximately two to three hours).
Norris F, Sheperd R, Denys E, et al.: Onset, natural history and outcome in idiopathic adult motor neuron disease. J Neurol Sci. 1993; 118(1): 48-55.
2.
Ringel SP, Murphy JR, Alderson MK, et al.: The natural history of amyotrophic lateral sclerosis. Neurology. 1993; 43(7): 1316-1322.
3.
Neilson S, Robinson I, Alperovitch A:Rising amyotrophic lateral sclerosis mortality in France 1968-1990: Increased life expectancy and inter-disease competition as an explanation. J Neurol. 1994; 241(7): 448-455.
4.
Neilson S, Robinson I, Nymoen EH:Longitudinal analysis of amyotrophic lateral sclerosis mortality in Norway, 1966-1989: Evidence for a susceptible subpopulation. J Neurol Sci. 1994; 122(2): 148-154.
5.
Eisen A:Amyotrophic lateral sclerosis is a multifactorial disease. Muscle Nerve. 1995; 18(7): 741-752.
6.
Eisen A, Schulzer M, MacNeil M, et al.: Duration of amyotrophic lateral sclerosis is age dependent. Muscle Nerve. 1993; 16: 27-32.
7.
Carter GT, Miller RG:Comprehensive management of amyotrophic lateral sclerosis. Phys Med Rehabil Clin N Am. 1998; 9(1): 271-284.
8.
Carter GT, Krivickas LS:Adult motor neuron disease. In Kirshblum S, Campagnolo DL, DeLisa JA, (eds.): Spinal Cord Injury Medicine. Philadelphia: Lippincott, Williams, and Wilkins, 2002.
9.
Carter GT, Rosen BS:Marijuana in the management of amyotrophic lateral sclerosis. Am J Hosp Palliat Care. 2001; 18(4): 264-270.
10.
Carter GT, Weydt P.Cannabis: Old medicine with new promise for neurological disorders. Curr Opin Investig Drugs. 2002; 3(3): 437-440.
11.
Weydt P, Weiss MD, Moller T, et al.: Neuroinflammation as a therapeutic target in amyotrophic lateral sclerosis. Curr Opin Investig Drugs. 2002; 3(12): 1720-1724.
12.
Hampson AJ, Grimaldi M, Axelrod J, et al.: Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA. 1998; 95(14): 8268-8273.
13.
Hampson AJ, Grimaldi M, Lolic M, et al.: Neuroprotective antioxidants from marijuana. Ann NY Acad Sci. 2000; 899: 274-282.
14.
Nagayama T, Sinor AD, Simon RP, et al.: Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci. 1999; 19(8): 2987-2995.
15.
Chen Y, Buck J:Cannabinoids protect cells from oxidative cell death: A receptor-independent mechanism. J Pharmacol Exp Ther. 2000; 293(3): 807-812.
16.
Eshhar N, Striem S, Biegon A:HU-211, a non-psychotropic cannabinoid, rescues cortical neurones from excitatory amino acid toxicity in culture. Neuroreport. 1993; 5(3): 237-240.
17.
Adams IB, Martin BR:Cannabis: Pharmacology and toxicology in animals and humans. Addiction. 1996; 91(11): 1585-1614.
18.
Agurell S, Halldin M, Lindgren JE, et al.: Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev. 1986; 38(1): 21-43.
19.
Johansson E, Halldin MM, Agurell S, et al.: Terminal elimination plasma half-life of delta 1-tetrahydrocannabinol (delta 1-THC) in heavy users of marijuana. Eur J Clin Pharmacol. 1989; 37(3): 273-277.
20.
Thomas BF, Adams IB, Mascarella SW, et al.: Structure-activity analysis of anandamide analogs: Relationship to a cannabinoid pharmacophore. J Med Chem. 1996; 39(2): 471-497.
21.
Mechoulam R, Devane WA, Breuer A, et al.: A random walk through a cannabis field. Special Issue: Pharmacological, chemical, biochemical and behavioral research on cannabis and the cannabinoids. Pharmacol Biochem Behav. 1991; 40(3): 461-464.
22.
Conrad C:Hemp for Health: The Medicinal and Nutritional Uses of Cannabis Sativa. Rochester, Vermont: Healing Arts Press, 1997.
23.
Jones RT:Drug of abuse profile: Cannabis. Clin Chem. 1987; 33(11 Suppl): 72B-81B.
24.
Jones RT, Benowitz NL, Herning RI:Clinical relevance of cannabis tolerance and dependence. J Clin Pharmacol. 1981; 21: 143S-152S.
25.
Polen MR, Sidney S, Tekawa IS, et al.: Health care use by frequent marijuana smokers who do not smoke tobacco. West J Med. 1993; 158(6): 596-601.
26.
Pope HG, Yurgelun-Todd D:The residual cognitive effects of heavy marijuana use in college students. JAMA. 1996; 275(7): 521-527.
27.
Renn E, Mandel S, Mandel E:The medicinal uses of marijuana. Pharm Ther. 2000; 25(10): 536-524.
Voth EA, Schwartz RH:Medicinal applications of delta-9-tetrahydrocannabinol and marijuana. Ann Intern Med. 1997; 126(10): 791-798.
30.
Cosroe P, Musty R, Rein J, et al.: The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol. 1997; 38: 44-48.
31.
Beal JE, Olson DO, Laubenstein L, et al.: Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage. 1995; 10: 89-97.
32.
Foltin RW, Fischman MW, Byrne MF:Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite. 1988; 11: 1-14.
33.
Greenberg I, Kuehnle J, Mendelson JH:Effects of marijuana use on body weight and caloric intake in humans. Psychopharmacology (Berl). 1976; 49: 79-84.
34.
Nelson K, Walsh D, Deeter P, et al.: A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care. 1994; 10(1): 14-18.
35.
Meinck HM, Schonle PW, Conrad B:Effects of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol. 1989; 263(2): 120-122.
36.
Greenberg HS, Weiness AS, Pugh JE:Short term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther. 1994; 55: 324-328.
37.
Renn E, Mandel S, Mandel E:The medicinal uses of marijuana. Pharm Ther. 2000; 25(10): 536-524.
Voth EA, Schwartz RH:Medicinal applications of delta-9-tetrahydrocannabinol and marijuana. Ann Intern Med. 1997; 126(10): 791-798.
40.
Meng ID, Manning BH, Martin WJ, et al.: An analgesia circuit activated by cannabinoids. Nature. 1998; 395(6700): 381-383.
41.
Noyes R, Brunk SF, Baram DA, et al.: Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol. 1975a; 15(2-3): 139-143.
42.
Zeltser R, Seltzer Z, Eisen A, et al.: Suppression of neuropathic pain behavior in rats by a non-psychotropic synthetic cannabinoid with NMDA receptor-blocking properties. Pain. 1991; 47(1): 95-103.
43.
Noyes R, Brunk SF, Avery DAH, et al.: The analgesic properties of delta-9-tetrahydrocannabinol. Clin Pharmacol Ther. 1975b; 18(1): 84-89.
44.
Richardson JD.Cannabinoids modulate pain by multiple mechanisms of action. J Pain. 2000; 1(1): 1-20.
45.
Carter GT, Butler LM, Abresch RT, et al.: Expanding the role of hospice in the care of amyotrophic lateral sclerosis. Am J Hosp Palliat Care. 1999; 16(6): 707-710.
46.
National Institute on Drug Abuse. Research Report Series: Marijuana Abuse. Bethesda, MD: National Institutes on Health, 2003.
Kehoe C, Pitkow J, Sutton K, et al.: Results of GVU’s Tenth World Wide Web User Survey. Georgia Institute of Technology, Graphics Visualization and Usability Center, College of Computing, Atlanta, Georgia. Available at www.gvu.gatech.edu/user_surveys/survey-1998-10/tenthreport.html. Accessed May 14, 1999.
49.
Leone M, Chandra V, Schoenberg BS:Motor neuron disease in the United States, 1971 and 1973-1978: Patterns of mortality and associated conditions at the time of death. Neurology. 1987; 37(8): 1339-1343.
50.
Lilienfeld DE, Chan E, Ehland J, et al.: Rising mortality from motoneuron disease in the USA, 1962-84. Lancet. 1989; 1(8640): 710-713.
51.
Kaye S:Computer and Internet Use Among People with Disabilities. Washington, DC: NIDRR, US Dept. of Education, 2000.
52.
Wasner M, Klier H, Borasio GD:The use of alternative medicine by patients with amyotrophic lateral sclerosis. J Neurol Sci. 2001; 191(1-2): 151-154.
53.
Mandler RN, Anderson FA, Miller RG, et al.: ALS C.A.R.E. Study Group. The ALS patient care database: Insights in to end-of-life care in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001; 2(4): 203-208.
